Zhong Nanshan: it will take time for related vaccines to be used in clinical practice

Novel coronavirus Huang Shuyuan Zhong Nanshan: the vaccine is still in clinical application In February 2nd, China's Academy of engineering, new group of coronavirus infection prevention and control mechanism, Zhong Nanshan, leader of the research group, said that we should have a scientific understanding of the 2019-nCoV pneumonia epidemic situation, and carry out scientific and effective prevention and control to avoid unnecessary panic Zhong Nanshan said there is no specific drug for 2019 ncov More clinical practice is needed to prove the efficacy of the drugs reported in some cases There are at least seven small molecule drugs targeting RNA polymerase or protease, including the above-mentioned cr3022 antibody drugs, which are in different clinical research stages; the development of related vaccines is also in progress, but it is still a long time before clinical application Experts report: the latest situation of epidemic drug research and development on February 4, sun Yanrong, deputy director of biological center of the Ministry of science and technology, said: in drug research and development, improving the cure rate and reducing the mortality rate are the top priority of emergency response The research and development of new drugs is a very long process The sudden epidemic situation makes it impossible for us to carry out our work according to the traditional law of new drug research and development The Ministry of science and technology organized relevant experts to tackle the problem at the first time, and has made some achievements Chloroquine phosphate, fabiravir and a batch of antiviral drugs in Chinese patent medicines have been found At present, Zhongsheng whole peptide has completed the preparation of about 500 million peptide information entity library, with a high-throughput new drug screening platform and team The company is also actively negotiating with the State Key Laboratory of infectious disease diagnosis and treatment of Zhejiang University, the State Key Laboratory of functional organic molecules of Lanzhou University and other parties to form a joint research and development team to conduct emergency research and development of anti-2019-ncov drugs In order to speed up the research and development process of the project, Zhongsheng quanpeptide has sent an invitation to the global teams and enterprises with new drug research and development capabilities, provided the world's largest peptide entity library free of charge, carried out all-round and open research and development cooperation at home and abroad, and worked together to overcome the difficulties and overcome the virus National Health and Health Commission: kelizhi and other drugs are undergoing clinical trials On February 4, 2020, the national health and Health Commission held a press conference Song Zhi, spokesman of the national health and Health Commission, said that the data of clinical trials of kelizhi and some traditional Chinese medicine are being collected Song said that in addition to the clinical trials of klitschke and some traditional Chinese medicine treatment, there is a drug called ridcivir recently Many medical institutions are carrying out clinical trials on the drug organization to study the safety and effectiveness of the drug Jeni turtle